Compare Stocks: OCUL, LNTH, BLTE, and AMRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$18.03 -0.6%	$16.79	$8.50 ▼ $19.26	$5.75B	1.27	2.16 million shs	694,719 shs
BLTE Belite Bio	$166.23 +2.0%	$149.58	$60.00 ▼ $200.00	$6.68B	-1.22	192,202 shs	98,404 shs
LNTH Lantheus	$100.92 0.0%	$104.09	$49.67 ▼ $111.86	$6.59B	-0.03	1.06 million shs	992,982 shs
OCUL Ocular Therapeutix	$9.20 +0.1%	$9.15	$6.23 ▼ $16.44	$2.02B	0.93	4.19 million shs	858,050 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	-0.98%	+6.64%	+41.94%	+112.41%
BLTE Belite Bio	0.00%	+2.80%	+9.19%	+7.29%	+133.33%
LNTH Lantheus	0.00%	+1.31%	-4.44%	+7.31%	+76.49%
OCUL Ocular Therapeutix	0.00%	+12.48%	-9.90%	-0.97%	-24.73%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMRX Amneal Pharmaceuticals	$18.03 -0.6%	$16.79	$8.50 ▼ $19.26	$5.75B	1.27	2.16 million shs	694,719 shs
BLTE Belite Bio	$166.23 +2.0%	$149.58	$60.00 ▼ $200.00	$6.68B	-1.22	192,202 shs	98,404 shs
LNTH Lantheus	$100.92 0.0%	$104.09	$49.67 ▼ $111.86	$6.59B	-0.03	1.06 million shs	992,982 shs
OCUL Ocular Therapeutix	$9.20 +0.1%	$9.15	$6.23 ▼ $16.44	$2.02B	0.93	4.19 million shs	858,050 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMRX Amneal Pharmaceuticals	0.00%	-0.98%	+6.64%	+41.94%	+112.41%
BLTE Belite Bio	0.00%	+2.80%	+9.19%	+7.29%	+133.33%
LNTH Lantheus	0.00%	+1.31%	-4.44%	+7.31%	+76.49%
OCUL Ocular Therapeutix	0.00%	+12.48%	-9.90%	-0.97%	-24.73%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMRX Amneal Pharmaceuticals	2.88	Moderate Buy	$17.67	-1.41% Downside
BLTE Belite Bio	2.88	Moderate Buy	$203.00	23.15% Upside
LNTH Lantheus	2.36	Hold	$108.11	7.09% Upside
OCUL Ocular Therapeutix	2.69	Moderate Buy	$25.75	182.81% Upside

Current Analyst Ratings Breakdown

Latest OCUL, LNTH, BLTE, and AMRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2026	LNTH Lantheus	CJS Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Outperform ➝ Market Perform
8/4/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
8/3/2026	LNTH Lantheus	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$125.00 ➝ $102.50
8/3/2026	LNTH Lantheus	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$110.00 ➝ $102.50
8/3/2026	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$102.50
8/3/2026	LNTH Lantheus	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$102.50
8/3/2026	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/3/2026	AMRX Amneal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$23.00 ➝ $25.00
8/3/2026	LNTH Lantheus	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/31/2026	LNTH Lantheus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
7/31/2026	AMRX Amneal Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$21.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMRX Amneal Pharmaceuticals	$3.02B	1.89	$1.54 per share	11.62	($0.23) per share	-77.91
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
LNTH Lantheus	$1.54B	4.27	$6.39 per share	15.81	$16.43 per share	6.14
OCUL Ocular Therapeutix	$51.95M	38.49	N/A	N/A	$3.07 per share	2.97

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMRX Amneal Pharmaceuticals	$72.06M	$0.49	36.58	15.86	N/A	5.05%	-584.46%	7.78%	N/A
BLTE Belite Bio	-$77.61M	-$2.53	N/A	N/A	N/A	N/A	-13.14%	-12.88%	8/13/2026 (Estimated)
LNTH Lantheus	$233.56M	$4.14	24.38	18.76	N/A	17.69%	28.10%	14.35%	N/A
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	N/A

Latest OCUL, LNTH, BLTE, and AMRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	BLTE Belite Bio	-$0.73	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	LNTH Lantheus	$1.30	$1.55	+$0.25	$1.11	$363.23 million	$388.18 million
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million
5/15/2026	Q1 2026	BLTE Belite Bio	-$0.60	-$0.34	+$0.26	-$0.68	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMRX Amneal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMRX Amneal Pharmaceuticals	77.65	2.20	1.44
BLTE Belite Bio	N/A	33.71	33.71
LNTH Lantheus	0.43	3.06	2.89
OCUL Ocular Therapeutix	0.14	13.10	13.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMRX Amneal Pharmaceuticals	31.82%
BLTE Belite Bio	0.53%
LNTH Lantheus	99.06%
OCUL Ocular Therapeutix	59.21%

Insider Ownership

Company	Insider Ownership
AMRX Amneal Pharmaceuticals	17.30%
BLTE Belite Bio	13.29%
LNTH Lantheus	1.70%
OCUL Ocular Therapeutix	3.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMRX Amneal Pharmaceuticals	8,500	319.02 million	263.83 million	Optionable
BLTE Belite Bio	10	40.08 million	34.76 million	Not Optionable
LNTH Lantheus	1,193	65.27 million	64.16 million	Optionable
OCUL Ocular Therapeutix	230	219.62 million	212.81 million	Optionable

OCUL, LNTH, BLTE, and AMRX Headlines

Recent News About These Companies

Ocular Therapeutix, Inc. $OCUL Shares Acquired by The Manufacturers Life Insurance Company

August 10 at 4:47 AM | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Upgraded at Wall Street Zen

August 8 at 2:13 AM | americanbankingnews.com

Ocular Therapeutix (NASDAQ:OCUL) Upgraded to "Hold" at Wall Street Zen

August 8 at 2:11 AM | marketbeat.com

HC Wainwright Issues Pessimistic Estimate for OCUL Earnings

August 8 at 1:28 AM | americanbankingnews.com

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 7 at 4:05 PM | globenewswire.com

HC Wainwright Has Negative Estimate for OCUL Q3 Earnings

August 6, 2026 | marketbeat.com

Ocular Therapeutix (NASDAQ:OCUL) Earns Buy Rating from Chardan Capital

August 6, 2026 | americanbankingnews.com

Ocular Therapeutix : OCUL

August 5, 2026 | 247wallst.com

Ocular Therapeutix's NDA Plans for Axpaxli in Wet AMD Remain on Track, RBC Says

August 5, 2026 | finance.yahoo.com

Chardan Capital Reiterates "Buy" Rating for Ocular Therapeutix (NASDAQ:OCUL)

August 4, 2026 | marketbeat.com

Ocular Therapeutix's Q2 Net Loss Widens, Revenue Flat

August 3, 2026 | finance.yahoo.com

Ocular Therapeutix (OCUL) Q2 2026 Earnings

August 3, 2026 | 247wallst.com

Ocular Therapeutix (NASDAQ:OCUL) beats expectations in strong Q2 CY2026

August 3, 2026 | msn.com

Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates

August 3, 2026 | zacks.com

Ocular Therapeutix (NASDAQ:OCUL) Posts Earnings Results, Beats Estimates By $0.05 EPS

August 3, 2026 | marketbeat.com

Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights

August 3, 2026 | globenewswire.com

Renaissance Technologies LLC Purchases 356,782 Shares of Ocular Therapeutix, Inc. $OCUL

August 3, 2026 | marketbeat.com

Defilade Capital Management L.P. Purchases 805,982 Shares of Ocular Therapeutix, Inc. $OCUL

August 3, 2026 | marketbeat.com

Ocular Therapeutix Inc 0OT

July 29, 2026 | morningstar.comM

Ocular Therapeutix™ Announces Proposed Public Offering of Common Stock

July 29, 2026 | businesswire.com

Readystate Asset Management LP Makes New Investment in Ocular Therapeutix, Inc. $OCUL

July 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, LNTH, BLTE, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

$18.04 -0.10 (-0.58%)

As of 03:38 PM Eastern

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Belite Bio NASDAQ:BLTE

$166.23 +3.18 (+1.95%)

As of 03:38 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Lantheus NASDAQ:LNTH

$100.92 -0.04 (-0.03%)

As of 03:38 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Ocular Therapeutix NASDAQ:OCUL

$9.20 +0.01 (+0.05%)

As of 03:38 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCUL, LNTH, BLTE, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCUL, LNTH, BLTE, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCUL, LNTH, BLTE, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, LNTH, BLTE, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Ocular Therapeutix NASDAQ:OCUL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest OCUL, LNTH, BLTE, and AMRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest OCUL, LNTH, BLTE, and AMRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

OCUL, LNTH, BLTE, and AMRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

OCUL, LNTH, BLTE, and AMRX Company Descriptions

Amneal Pharmaceuticals NASDAQ:AMRX

Belite Bio NASDAQ:BLTE

Lantheus NASDAQ:LNTH

Ocular Therapeutix NASDAQ:OCUL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools